All In Biotech

Drug Trial Radar · NCT07221149

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 690 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

690

Planned (sponsor's estimate)

Start

Mar 13, 2026

Primary completion

Nov 8, 2030

Study completion Sep 11, 2032

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma

Conditions

  • Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Interventions

  • PumitamigDrug

    Specified dose on specified days

  • FolfoxDrug

    Specified dose on specified days

  • CapoxDrug

    Specified dose on specified days

  • NivolumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessmentTime frame: Up to 2 years after the last participant is randomized
  2. Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)Time frame: Up to approximately 33 months
  3. Overall survival (OS)Time frame: Up to approximately 47 months

Locations

161 sites in 20 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center

    Orange, California · Recruiting

  • Local Institution - 0428

    San Francisco, California · Not yet recruiting

  • Florida Cancer Specialists - South

    Fort Myers, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Florida Cancer Specialists - North

    St. Petersburg, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Local Institution - 0379

    Chicago, Illinois · Not yet recruiting

  • Local Institution - 0268

    Iowa City, Iowa · Not yet recruiting

  • Mayo Clinic in Rochester, Minnesota

    Rochester, Minnesota · Recruiting

  • Missouri Cancer Associates

    Columbia, Missouri · Recruiting

  • University Of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • Northwell Health/ RJ Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Local Institution - 0274

    Rochester, New York · Not yet recruiting

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina · Recruiting

  • Local Institution - 0443

    Cleveland, Ohio · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Oncology Associates Of Oregon, Pc

    Eugene, Oregon · Recruiting

  • Northwest Cancer Specialists, P.C.

    Portland, Oregon · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Amarillo Cancer Center

    Amarillo, Texas · Recruiting

  • Texas Oncology-Austin Central

    Austin, Texas · Recruiting

  • Texas Oncology

    Beaumont, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Denison, Texas · Recruiting

  • Texas Oncology - DFW

    Grapevine, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology - San Antonio

    San Antonio, Texas · Recruiting

  • Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem

    Salem, Virginia · Recruiting

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin · Recruiting

  • Local Institution - 0300

    · Not yet recruiting

  • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)

    Buenos Aires, Argentina · Recruiting

  • Centro Médico Fleischer

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    ABB, Buenos Aires F.D., Argentina · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.